AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Fenbufen is effective in reducing mild to moderate pain, including headache, toothache, muscle pain, menstrual cramps, and pain caused by minor injuries. It works by inhibiting the production of prostaglandins, which are substances in the body that contribute to pain and inflammation.
Anti-inflammatory Effects: Fenbufen helps reduce inflammation by inhibiting the activity of cyclooxygenase enzymes (COX-1 and COX-2), which are involved in the synthesis of prostaglandins. By decreasing the levels of prostaglandins, fenbufen helps alleviate swelling, redness, and discomfort associated with inflammatory conditions such as arthritis, bursitis, and tendonitis.
Antipyretic Action: Fenbufen can lower fever by acting on the hypothalamus, a region of the brain that regulates body temperature. By inhibiting prostaglandin synthesis, it reduces fever and promotes temperature normalization in individuals with febrile conditions.
Musculoskeletal Disorders: Fenbufen is commonly prescribed for the management of musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. It helps relieve joint pain, stiffness, and swelling, thereby improving mobility and overall quality of life.
Dysmenorrhea: Fenbufen is often used to alleviate menstrual pain (dysmenorrhea) and discomfort associated with menstrual cramps. Its analgesic and anti-inflammatory properties help reduce pelvic pain and uterine contractions, providing relief during menstruation.
Adverse Effects: Like other NSAIDs, fenbufen may cause gastrointestinal side effects such as stomach pain, nausea, indigestion, and gastrointestinal bleeding or ulcers, particularly with long-term use or at high doses. It may also increase the risk of cardiovascular events such as heart attack or stroke, especially in individuals with pre-existing cardiovascular conditions.
Renal Effects: Prolonged use of fenbufen or other NSAIDs may lead to kidney-related adverse effects, including fluid retention, decreased kidney function, and kidney damage. Patients with pre-existing renal impairment or dehydration are at higher risk of developing these complications.
Hepatic Effects: Fenbufen has the potential to cause liver damage, hepatotoxicity, or abnormal liver function tests, although such adverse effects are relatively rare. Patients with underlying liver disease or alcoholism may be more susceptible to liver-related complications.
Allergic Reactions: Some individuals may experience allergic reactions to fenbufen, manifesting as rash, itching, hives, swelling of the face or throat, difficulty breathing, or anaphylaxis. Allergic reactions require immediate medical attention and discontinuation of the medication.
Drug Interactions: Fenbufen may interact with other medications, including anticoagulants, antiplatelet drugs, corticosteroids, selective serotonin reuptake inhibitors (SSRIs), and certain herbal supplements. Concurrent use of fenbufen with these medications may increase the risk of bleeding or other adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.2 | -0.2 | |
| ADHD | 3.8 | 0 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.2 | 0.5 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 1.2 | 0 |
| Allergies | 2.9 | 2.4 | 0.21 |
| Allergy to milk products | 1.4 | 0.7 | 1 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 3.8 | 3.2 | 0.19 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 1.6 | 0.63 |
| Ankylosing spondylitis | 2.2 | 1.1 | 1 |
| Anorexia Nervosa | 0.2 | 1.4 | -6 |
| Antiphospholipid syndrome (APS) | 2 | 2 | |
| Asthma | 0.6 | 1.9 | -2.17 |
| Atherosclerosis | 1.1 | 1.7 | -0.55 |
| Atrial fibrillation | 2.1 | 1 | 1.1 |
| Autism | 6.8 | 6.1 | 0.11 |
| Barrett esophagus cancer | 0.9 | 0.3 | 2 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 1 | 0.8 | 0.25 |
| Brain Trauma | 0.4 | 0.5 | -0.25 |
| Carcinoma | 2.2 | 1.7 | 0.29 |
| Celiac Disease | 2 | 2.8 | -0.4 |
| Cerebral Palsy | 1.7 | 1 | 0.7 |
| Chronic Fatigue Syndrome | 3.6 | 3.7 | -0.03 |
| Chronic Kidney Disease | 0.9 | 0.3 | 2 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 0.2 | 10.5 |
| Chronic Urticaria (Hives) | 1.7 | 1.5 | 0.13 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 1 | 0.2 |
| Colorectal Cancer | 4.6 | 0.4 | 10.5 |
| Constipation | 0.9 | 0.4 | 1.25 |
| Coronary artery disease | 0.4 | 0.6 | -0.5 |
| COVID-19 | 9.5 | 9.5 | 0 |
| Crohn's Disease | 6 | 3.4 | 0.76 |
| cystic fibrosis | 0.7 | 0.8 | -0.14 |
| deep vein thrombosis | 0.7 | 0.7 | 0 |
| Depression | 7.9 | 6.1 | 0.3 |
| Dermatomyositis | 0.3 | 0.2 | 0.5 |
| Eczema | 0.6 | 1.9 | -2.17 |
| Endometriosis | 2.1 | 0.8 | 1.63 |
| Eosinophilic Esophagitis | 0.5 | 0.4 | 0.25 |
| Epilepsy | 2.9 | 3.1 | -0.07 |
| Fibromyalgia | 2.1 | 1.1 | 0.91 |
| Functional constipation / chronic idiopathic constipation | 4.7 | 2.7 | 0.74 |
| gallstone disease (gsd) | 1.8 | 0.9 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.8 | 1.25 |
| Generalized anxiety disorder | 1.4 | 1.3 | 0.08 |
| giant cell arteritis | 0.4 | -0.4 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0 | 0 | |
| Graves' disease | 0.9 | 0.6 | 0.5 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 1.6 | 0.6 | 1.67 |
| Hidradenitis Suppurativa | 0.8 | 0.4 | 1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.1 | 0.3 | 6 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.9 | -0.5 |
| hyperglycemia | 0.2 | 2.4 | -11 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.1 | 7 |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 2.1 | 3.7 | -0.76 |
| Hypothyroidism | 0.5 | -0.5 | |
| Hypoxia | 1 | 1 | |
| IgA nephropathy (IgAN) | 2.7 | -2.7 | |
| Inflammatory Bowel Disease | 2.9 | 5.1 | -0.76 |
| Insomnia | 0.9 | 0.5 | 0.8 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 1.1 | 0.1 | 10 |
| Irritable Bowel Syndrome | 5.2 | 3.8 | 0.37 |
| Liver Cirrhosis | 4 | 2.6 | 0.54 |
| Long COVID | 5.9 | 5.5 | 0.07 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 1.1 | 1.4 | -0.27 |
| ME/CFS with IBS | 0.9 | 1.2 | -0.33 |
| ME/CFS without IBS | 0.8 | 0.9 | -0.13 |
| Menopause | 2 | 2 | |
| Metabolic Syndrome | 5.9 | 6.9 | -0.17 |
| Mood Disorders | 10.7 | 6.1 | 0.75 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.2 | 6.5 |
| Multiple Sclerosis | 4.6 | 3.1 | 0.48 |
| Multiple system atrophy (MSA) | 2.6 | 0.7 | 2.71 |
| Neuropathy (all types) | 1 | 0.2 | 4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 3.6 | -1.77 |
| NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
| Obesity | 5.3 | 4.4 | 0.2 |
| obsessive-compulsive disorder | 5.6 | 2.1 | 1.67 |
| Osteoarthritis | 1.5 | 0.2 | 6.5 |
| Osteoporosis | 1.6 | 1.5 | 0.07 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 2.7 | 3 | -0.11 |
| Polycystic ovary syndrome | 2 | 1.9 | 0.05 |
| Postural orthostatic tachycardia syndrome | 0.4 | 0.2 | 1 |
| Premenstrual dysphoric disorder | 0.6 | 0.2 | 2 |
| primary biliary cholangitis | 0.1 | 0.3 | -2 |
| Psoriasis | 3.6 | 1.8 | 1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.8 | 3 | 0.27 |
| Rosacea | 0.6 | 0.6 | 0 |
| Schizophrenia | 5.3 | 1.3 | 3.08 |
| scoliosis | 0 | 0.2 | 0 |
| Sjögren syndrome | 2.4 | 1.9 | 0.26 |
| Sleep Apnea | 1.2 | 0.8 | 0.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.4 | 2 |
| Stress / posttraumatic stress disorder | 2.8 | 1.8 | 0.56 |
| Systemic Lupus Erythematosus | 3 | 1.1 | 1.73 |
| Tic Disorder | 0.8 | 0.4 | 1 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3.4 | 1.8 | 0.89 |
| Type 2 Diabetes | 5.9 | 6.6 | -0.12 |
| Ulcerative colitis | 2.5 | 4.5 | -0.8 |
| Unhealthy Ageing | 4.3 | 1.1 | 2.91 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.